文献速递脑血管病

MRI筛查的轻型卒中静脉tPA治疗患者影像靶标患病率:TIMES研究

Prevalence of Imaging Targets in Patients With Minor Stroke Selected for IV tPA Treatment Using MRI: The Treatment of Minor Stroke With MRI Evaluation Study (TIMES).
PubMed 文献 · Neurology · 2021-01-20

本研究评估了发病4.5小时内轻型急性缺血性卒中(NIHSS<6)患者接受静脉tPA治疗的比例,并比较治疗组与未治疗组基线MRI影像靶标的发生频率。结果显示,255例患者中140例(55%)接受tPA,占所有tPA患者的46%;治疗组影像靶标更常见,且即使在无明确致残性缺损的患者中频率相似。作者认为MRI靶标或可指导轻型卒中溶栓决策,但需随机试验验证疗效。

要点

  • 轻型卒中4.5小时内55%接受静脉tPA,占全部tPA患者的46%。
  • tPA治疗组基线MRI影像靶标频率显著高于未治疗组。
  • 治疗组中75%无明确致残性缺损,除灌注-弥散错配外影像靶标频率无显著差异。

核心结论

  • 在MRI筛查的轻型急性缺血性卒中患者中,接受静脉tPA治疗者影像靶标更常见,且无明确致残性缺损者频率相似。
  • MRI靶标有望指导轻型卒中溶栓治疗,但需随机试验证实疗效。

研究设计与样本

  • 回顾性队列研究,纳入2015至2017年发病4.5小时内、入院NIHSS<6的缺血性卒中患者255例。
  • 治疗组接受标准静脉tPA并做基线MRI筛查;未治疗组无急性干预且基线MRI在发病4小时内完成。
  • 由独立评估者判读基线MRI的AIS靶标,比较组间频率。

主要发现

  • 255例轻型卒中患者中140例(55%)接受静脉tPA,占所有静脉tPA患者(n=305)的46%。
  • 治疗组中89例(75%)无明确致残性缺损。
  • 按临床严重程度分层,除灌注-弥散错配外(明确致残组81% vs 非明确致残组56%,p=0.036),影像靶标频率无显著差异。

临床怎么用

  • 对MRI筛查的轻型卒中患者,影像靶标可辅助识别适合静脉tPA治疗的人群。
  • 无明确致残性缺损的轻型卒中患者也可能存在影像靶标,不应仅凭临床严重程度排除溶栓。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the IV tissue plasminogen activator (tPA) treatment rate of patients with minor acute ischemic stroke (mAIS) at our centers and compare the frequency of MRI targets by treatment stratification and clinical severity, we evaluated clinical characteristics and baseline MRIs for tPA-treated and untreated patients. METHODS: Patients with ischemic stroke from 2015 to 2017 with admit NIH Stroke Scale (NIHSS) <6 were considered. The treated cohort received standard IV tPA and was screened with baseline MRI. The untreated cohort received no acute intervention and baseline MRI was <4 hours from onset. Patients were stratified into "clearly" and "not clearly" disabling deficits by NIHSS elements. Baseline MRI was evaluated by independent raters for AIS targets, with frequencies compared between groups. RESULTS: Of 255 patients with mAIS ≤4.5 hours from onset, 140 (55%) received IV tPA, accounting for 46% of all IV tPA patients (n = 305). Eighty-five percent (n = 119) were screened with baseline MRI and had significantly more frequent imaging targets compared to those untreated (n = 90). Of this treated cohort, 75% (n = 89) were not clearly disabling. Except for perfusion-diffusion mismatch (81% clearly disabling vs 56% not clearly disabling [p = 0.036]), there were no significant differences in the frequency of imaging targets across the treated cohort stratified by clinical severity. CONCLUSIONS: In MRI-screened mAIS, imaging targets were more frequently seen in patients treated with IV tPA, with similar frequencies even in those without clearly disabling deficits. MRI targets could be used to guide thrombolytic therapy in patients with mAIS; however, a randomized trial is needed to demonstrate efficacy.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Hsia AW, Luby ML, Leigh R, et al. Prevalence of Imaging Targets in Patients With Minor Stroke Selected for IV tPA Treatment Using MRI: The Treatment of Minor Stroke With MRI Evaluation Study (TIMES). Neurology. 2021. PMID: 33472921. doi:10.1212/WNL.0000000000011527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。